Education
About Us
Working with TipRanks
Follow Us
Disc Medicine (IRON)
NASDAQ:IRON
IRON Stock Chart & Stats
$93.75
$0.74(1.19%)
At close: 4:00 PM EST
$93.75
$0.74(1.19%)
Day’s Range― - ―
52-Week Range$30.82 - $97.12
Previous CloseN/A
Volume41.94K
Average Volume (3M)629.25K
Market Cap
$3.54B
Enterprise Value$1.74B
Total Cash (Recent Filing)$615.92M
Total Debt (Recent Filing)$30.98M
Price to Earnings (P/E)―
Beta1.75
Next Earnings
Mar 27, 2026EPS Estimate
-1.67Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.77
Shares Outstanding37,750,160
10 Day Avg. Volume651,167
30 Day Avg. Volume629,250
Financial Highlights & Ratios
PEG Ratio-1.01
Price to Book (P/B)3.95
Price to Sales (P/S)0.00
P/FCF Ratio-18.53
Enterprise Value/Market Cap0.49
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-18.12K
Enterprise Value/Ebitda-10.76
Forecast
1Y Price Target
$114.91Price Target Upside22.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-5.97
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
FDA Approval And Accelerated ReviewThe FDA announced that bitopertin has been selected as one of the first nine recipients of the Commissioner’s National Priority Review Voucher for the treatment of erythropoietic protoporphyria, accelerating the drug application review timelines to 1-2 months.
Financial Position And Cash RunwayDisc Medicine has a strong financial position, ending the period with $615.9M in cash, cash equivalents, and investments, and extending its cash runway into 2029 after a public offering.
Market Potential And Commercial OpportunityBitopertin is a first-in-class opportunity in erythropoietic protoporphyria (EPP), a rare and debilitating disorder with no disease-modifying treatments available.
Bears Say
Clinical Trial ConcernsUpdates indicated Ph 1b hemoglobin responses for DISC-0974 in CKD-anemia were 'observed in only a subset of patients,' lowering our confidence in the indication.
Commercialization RiskDisc Medicine has never commercialized a product, which poses a risk for the successful launch and commercialization of bitopertin.
Regulatory ConcernsConcerns exist about the FDA's ability to meet the expedited review timeline due to recent leadership changes and workforce shortages.
Disc Medicine News
IRON FAQ
What was Disc Medicine’s price range in the past 12 months?
Disc Medicine lowest stock price was $30.82 and its highest was $97.11 in the past 12 months.
What is Disc Medicine’s market cap?
Disc Medicine’s market cap is $3.54B.
When is Disc Medicine’s upcoming earnings report date?
Disc Medicine’s upcoming earnings report date is Mar 27, 2026 which is in 118 days.
How were Disc Medicine’s earnings last quarter?
Disc Medicine released its earnings results on Nov 06, 2025. The company reported -$1.77 earnings per share for the quarter, missing the consensus estimate of -$1.442 by -$0.328.
Is Disc Medicine overvalued?
According to Wall Street analysts Disc Medicine’s price is currently Undervalued.
Does Disc Medicine pay dividends?
Disc Medicine does not currently pay dividends.
What is Disc Medicine’s EPS estimate?
Disc Medicine’s EPS estimate is -1.67.
How many shares outstanding does Disc Medicine have?
Disc Medicine has 37,750,160 shares outstanding.
What happened to Disc Medicine’s price movement after its last earnings report?
Disc Medicine reported an EPS of -$1.77 in its last earnings report, missing expectations of -$1.442. Following the earnings report the stock price went down -1.483%.
Which hedge fund is a major shareholder of Disc Medicine?
Currently, no hedge funds are holding shares in IRON
Disc Medicine Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$114.91 (22.57% Upside)
$114.91 (22.57% Upside)
Blogger Sentiment
Bullish
IRON Sentiment 100%
Sector Average 69%
Sector Average 69%
Insider Transactions
Sold Shares
Worth $74.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.2%
Last 30 Days ▲ 5.8%
Last 30 Days ▲ 5.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
49.64%
12-Months-Change
Fundamentals
Return on Equity
-34.78%
Trailing 12-Months
Asset Growth
27.33%
Trailing 12-Months
Company Description
Disc Medicine
Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. It builds a portfolio of therapeutic candidates that address a spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, primarily heme biosynthesis and iron homeostasis. The company is based in Watertown, Massachusetts.
IRON Stock 12 Month Forecast
Average Price Target
$114.91
▲(22.57% Upside)
Technical Analysis
Agios Pharma
―
Travere Therapeutics
―
Arcutis Biotherapeutics
―
Tarsus Pharmaceuticals
―
Recursion Pharmaceuticals
―
Ownership Overview
10.85% Insiders
23.11% Mutual Funds
39.45% Other Institutional Investors
17.94% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---